According to some reports, about one-fourth of CML patients were declared high-risk at 3 months (with BCR-ABLIS >10%) and the same proportion of treatment failure was also observed in the IRIS study. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.